Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Sepe

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
BMJ Case Reports|January 12, 2017
Pancreatic lymphoma complicating early stage chronic hepatitis CVicky H Bhagat, Thomas Sepe
Cleveland Clinic Journal of Medicine|October 6, 2018
Correction: Liver enzymesBrian Agganis, David Lee, Thomas Sepe
Cleveland Clinic Journal of Medicine|August 14, 2018
Liver enzymes: No trivial elevations, even if asymptomaticBrian Agganis, David Lee, Thomas Sepe
Hepatology Communications|June 22, 2023
Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.SMegan Glynn, Chari Cohen, Robert G Gish, et al.
Annals of Hepatology|December 15, 2011
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patientsDavid R Nelson, Stefan Zeuzem, Pietro Andreone, et al.
JAMA|May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infectionFred Poordad, William Sievert, Lindsay Mollison, et al.
The New England Journal of Medicine|May 6, 2014
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCVPeter Ferenci, David Bernstein, Jacob Lalezari, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
BMJ Case Reports|January 12, 2017
Pancreatic lymphoma complicating early stage chronic hepatitis CVicky H Bhagat, Thomas Sepe
Cleveland Clinic Journal of Medicine|October 6, 2018
Correction: Liver enzymesBrian Agganis, David Lee, Thomas Sepe
Cleveland Clinic Journal of Medicine|August 14, 2018
Liver enzymes: No trivial elevations, even if asymptomaticBrian Agganis, David Lee, Thomas Sepe
Hepatology Communications|June 22, 2023
Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.SMegan Glynn, Chari Cohen, Robert G Gish, et al.
Annals of Hepatology|December 15, 2011
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patientsDavid R Nelson, Stefan Zeuzem, Pietro Andreone, et al.
JAMA|May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infectionFred Poordad, William Sievert, Lindsay Mollison, et al.
The New England Journal of Medicine|May 6, 2014
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCVPeter Ferenci, David Bernstein, Jacob Lalezari, et al.
Pageof 1